ISR - IsoRay, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.7190
+0.0101 (+1.42%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.7089
Open0.7045
Bid0.6966 x 3000
Ask0.7118 x 1000
Day's Range0.6908 - 0.7400
52 Week Range0.2900 - 1.0600
Volume211,106
Avg. Volume466,766
Market Cap48.641M
Beta (5Y Monthly)1.87
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
All
News
Press Releases
  • GlobeNewswire

    Isoray Announces Record Third Quarter Fiscal 2020 Financial Results

    RICHLAND, Wash., May 12, 2020 -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options.

  • GlobeNewswire

    Centers for Medicare and Medicaid Services Approves Isoray’s Application for Billing Codes for the Intraoperative Use of Cesium-131

    Isoray, Inc. (NYSE American: ISR) today announced that the Centers for Medicare and Medicaid Services (CMS) has approved 64 ICD-10-PCS billing codes used for reimbursement of Cesium-131 (Cesium Blu™) for the hospital in-patient DRG setting. The codes allow hospitals to bill Medicare and other health insurers for specific surgical procedures that would benefit from the addition of Cesium-131. DRG or diagnostic related groups are designed for Medicare and other health insurers to set payment levels for hospital in-patient services.

  • GlobeNewswire

    Isoray To Announce Third Quarter Fiscal 2020 Financial Results on May 12, 2020

    Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body, today announced that it will host a conference call to discuss its financial results for the third quarter fiscal 2020 ended March 31, 2020 on Tuesday, May 12, 2020, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the third quarter fiscal 2020 after the close of the U.S. stock markets on May 12, 2020. To listen to the conference call, please dial 844-602-0380.

  • GlobeNewswire

    Isoray Announces Second Quarter Fiscal 2020 Financial Results

    Revenue Increased 16% Year-Over-YearGross Profit Increased 45% Year-Over-Year RICHLAND, Wash., Feb. 11, 2020 -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology.

  • GlobeNewswire

    Isoray Collaborates with MIM Software to Deliver an Advanced Treatment Solution for Recurrent Head and Neck Cancers

    Isoray, Inc. (NYSE American: ISR) today announced an executed agreement with MIM Software to deliver a novel one-stop-provides-all program to treat head and neck cancer. The new offering bundles MIM’s software technology and Isoray’s industry leading Cesium Blu™, also known as Cesium-131, brachytherapy expanding treatment options and access for physicians and patients. Cesium Blu brachytherapy delivers a highly targeted treatment to the site of the disease, preserving healthy tissue and organs.

  • GlobeNewswire

    Isoray To Announce Second Quarter Fiscal 2020 Financial Results on February 11, 2020

    RICHLAND, Wash., Jan. 31, 2020 -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options.

  • GlobeNewswire

    Isoray Announces Record First Quarter Fiscal 2020 Financial Results

    Record Revenue and Gross ProfitRevenue Increased 48% Year-Over-Year RICHLAND, Wash., Nov. 12, 2019 -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and.

  • GlobeNewswire

    Isoray To Announce First Quarter Fiscal 2020 Financial Results on November 12, 2019

    RICHLAND, Wash., Oct. 31, 2019 --  Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options.

  • GlobeNewswire

    Isoray Will Have Prominent Role at American Brachytherapy Society’s Annual Prostate Brachytherapy Workshop

    RICHLAND, Wash., Oct. 29, 2019 (GLOBE NEWSWIRE) --  Isoray, Inc. (NYSE AMERICAN: ISR)  announced today that it will demonstrate its latest products at the American Brachytherapy Society’s (ABS) annual prostate brachytherapy workshop. The workshop is scheduled to take place November 1-2 at the Hyatt Regency Denver at Colorado Convention Center in Denver, Colorado. The workshop’s Co-Chairmen are Dr. Brett W. Cox, Interim Chairman of the Department of Radiation Medicine at Lenox Hill Hospital and Chief of Brachytherapy for Northwell Health, and Dr. Peter J. Rossi, Calaway Young Cancer Center and Valley View Hospital.

  • GlobeNewswire

    Isoray Announces Fourth Quarter and Full-Year Fiscal 2019 Financial Results

    Record Full Year Revenue Driven by 27% Growth in the Company’s Core Prostate Brachytherapy RICHLAND, Wash., Sept. 24, 2019 -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical.

  • ACCESSWIRE

    IsoRay, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / September 24, 2019 / IsoRay, Inc. (NYSEMKT: ISR ) will be discussing their earnings results in their 2019 Fourth Quarter Earnings to be held on September 24, 2019 at 4:30 PM ...

  • GlobeNewswire

    A Decade of Data Shows the Value of Isoray’s Cesium-131 As Prostate Cancer Internal Radiation Therapy Treatment

    A recent publication is drawing attention for its positive report on a study of the ten-year findings on the impact of Cesium-131 internal radiation therapy in treating a series of cancer patients. The peer reviewed publication, Long-term Biochemical Outcomes Using Cesium-131 in Prostate Brachytherapy, was recently made available on the website of BRACHYTHERAPY, an international multidisciplinary journal. The publication reported on a study of a series of 571 patients who were treated with Cesium-131 prostate brachytherapy at the Chicago (IL) Prostate Cancer Center by radiation oncologist Dr. Brian J. Moran.

  • GlobeNewswire

    Isoray To Announce Fourth Quarter and Year End 2019 Financial Results on September 24, 2019

    RICHLAND, Wash., Sept. 12, 2019 -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options.

  • GlobeNewswire

    Isoray To Spotlight Cesium-131 Advances in Treating Hard to Treat Cancers at the American Society for Radiation Oncology Annual Meeting 

    Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, announced today that it will spotlight the growing cancer treatment applications of Cesium-131 at the American Society for Radiation Oncology (ASTRO) annual meeting. During the meeting, attendees will have the opportunity to learn about the mounting body of clinical evidence illustrating the expanding use of Cesium-131, now known as Cesium BluTM, and its effectiveness in treating recurrent brain cancers including meningiomas and brain metastases. Attendees will also get a first-hand look at the innovative Blu Build real-time Cesium-131 internal radiation therapy delivery system.

  • GlobeNewswire

    Efficacy of Isoray’s Cesium Blu Showcased in Recent Studies

    Studies recently reported at scientific meetings and published in medical journals illustrate that Isoray, Inc.’s (NYSE AMERICAN: ISR) Cesium Blu™ is making an important difference in providing treatment options for cancer patients and their doctors. Isoray expects the growing volume of results-based data on Cesium Blu, formerly known as Cesium-131, will help grow market awareness of the range of clinical applications. Among the recent studies are the findings of Dr. David Brachman of the Barrow Neuroscience Institute on the impact of Cesium Blu-driven treatment on three types of recurrent brain cancers.

  • GlobeNewswire

    Isoray To Launch The Power of Blu Introducing A New Brand Identity at the American Brachytherapy Society’s Annual Meeting

    RICHLAND, Wash., June 12, 2019 (GLOBE NEWSWIRE) --  Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it will launch The Power of Blu™ campaign introducing a new look and feel for the Cesium product group at the American Brachytherapy Society’s (ABS) annual meeting. The initiative introduces the new brand identity for Isoray’s innovative product offerings and focuses on raising awareness of the important advances in the treatment of cancers utilizing brachytherapy powered by Cesium-131, now known as Cesium Blu™.